LUTS: Lower Urinary Tract Symptoms最新文献

{"title":"Association Between Prior Inguinal Hernia Repair and Early Continence Recovery After Robot-Assisted Radical Prostatectomy.","authors":"Sung Jin Kim, Sung Gon Park, Sahyun Pak, Ohseong Kwon, Young Goo Lee, Sung Tae Cho","doi":"10.1111/luts.70069","DOIUrl":"10.1111/luts.70069","url":null,"abstract":"<p><strong>Objective: </strong>Early post-prostatectomy incontinence (PPI) remains a common concern after robot-assisted radical prostatectomy (RARP). Recovery patterns vary among individuals, and identifying patients at risk of delayed recovery is clinically important. We evaluated whether prior adult inguinal hernia (IH) repair is associated with early continence outcomes after RARP.</p><p><strong>Methods: </strong>We retrospectively analyzed 305 consecutive patients who underwent RARP between 2021 and 2024. Continence was defined as pad-free status, and PPI as use of > 1 pad/day. Continence was assessed at 1 week and at 1, 3, and 6 months postoperatively. Multivariable logistic regression and generalized estimating equation (GEE) modeling were used to evaluate associations, adjusting for age and BMI. Kaplan-Meier and interval-censored Cox models were applied to assess time to continence.</p><p><strong>Results: </strong>Twenty-seven patients (8.9%) had prior IH repair. These patients demonstrated significantly higher rates of PPI at all assessed time points. After adjustment for age and BMI, prior IH repair remained significantly associated with PPI (adjusted ORs 2.99-5.84, all p < 0.05). Longitudinal GEE analysis also suggested a slower recovery pattern in the IH group (adjusted OR 4.05, 95% CI 1.62-10.11, p = 0.003). Kaplan-Meier analysis demonstrated delayed return to continence (log-rank p < 0.001), and interval-censored Cox regression confirmed a significantly lower probability of continence recovery in this group (p = 0.001).</p><p><strong>Conclusions: </strong>Prior IH repair was associated with delayed early continence recovery within 6 months after RARP. Given the limited IH sample and follow-up duration, these findings should be interpreted cautiously as exploratory and hypothesis-generating. Larger prospective studies with longer follow-up are warranted.</p>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":"e70069"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147982003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148097118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148090747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148077977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Frailty and Short-Term Treatment-Related Adverse Events in Patients With Overactive Bladder","authors":"Sohei Iwagami,&nbsp;Hiraku Yamamoto,&nbsp;Haruka Miyai,&nbsp;Masaya Nishihata","doi":"10.1111/luts.70060","DOIUrl":"10.1111/luts.70060","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate whether frailty at treatment initiation is associated with treatment-related adverse events in patients with newly diagnosed overactive bladder (OAB).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective, single-center cohort study included 122 patients who initiated pharmacotherapy for OAB between April 2024 and January 2026. Frailty was evaluated using the Frailty Screening Index and classified as robust, prefrail, or frail. The primary outcome was treatment-related adverse events within 3 months, and independent predictors were identified using multivariable logistic regression. Longitudinal changes in OAB symptoms were examined using linear mixed-effects models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During follow-up, adverse events occurred in 52 patients (42.6%), rising with frailty (4.7%, 40.0%, and 57.3% in robust, prefrail, and frail groups, respectively; <i>p</i> &lt; 0.01 for trend). In multivariable analysis, frailty (odds ratio [OR] 2.97 per status increase, 95% confidence interval [CI] 1.45–6.52; <i>p</i> &lt; 0.01), anticholinergic use (OR 7.96, 95% CI 2.94–24.46; <i>p</i> &lt; 0.01), and baseline post-void residual volume (OR 1.22 per 10 mL increase, 95% CI 1.01–1.34; <i>p</i> = 0.02) were independently associated with adverse events; chronological age was not. Symptom improvement over time did not differ significantly by frailty status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Frailty, rather than chronological age, was associated with short-term treatment-related adverse events among patients starting pharmacotherapy for OAB. Frailty assessment may help identify patients at higher risk of adverse events and support individualized, safety-conscious treatment decisions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Early Postoperative Urinary Incontinence on Presenteeism After Robot-Assisted Radical Prostatectomy for Prostate Cancer: A Prospective Cohort Study","authors":"Noriko Nakayama,&nbsp;Tetsuya Tsuji,&nbsp;Akira Kumagai","doi":"10.1111/luts.70055","DOIUrl":"10.1111/luts.70055","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Urinary incontinence (UI) in the first 3 months after robot-assisted radical prostatectomy (RARP) frequently impairs work performance, yet its quantitative impact on presenteeism remains unclear. This prospective cohort study longitudinally evaluated how early postoperative UI influences presenteeism among employed Japanese men undergoing RARP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We consecutively enrolled 92 employed male patients scheduled for RARP and assessed them preoperatively, at discharge, and at 1- (PS-1) and 3-month (PS-3) post-surgery. Outcomes were the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), WHO Health and Work Performance Questionnaire (HPQ)-Presenteeism Scale, King's Health Questionnaire (KHQ), and Kessler Psychological Distress Scale (K6).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 92 eligible participants, 85 (92.4%) completed the PS-1 and 80 (87.0%) completed the PS-3 assessment. Median ICIQ-SF total scores increased from 0 (IQR 0–2) preoperatively to 9 (6–12) at PS-1, remaining elevated at 7 (4–10) at PS-3 (<i>p</i> &lt; 0.001). Mean HPQ-presenteeism declined from 81.4% ± 13.9% preoperatively to 64.9% ± 18.8% at PS-1, partially recovering to 75.3% ± 16.1% at PS-3 (<i>p</i> &lt; 0.001). At PS-1, UI impact on daily life (<i>ρ</i> = −0.45) and ICIQ-SF total (<i>ρ</i> = −0.43) were moderately associated with lower presenteeism; at PS-3, correlations persisted and extended to multiple KHQ subscales (<i>ρ</i> = −0.41 to −0.53).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Early postoperative UI after RARP produces a clinically meaningful reduction in work productivity, greatest at PS-1 and still evident at PS-3. Targeted continence care and occupational support during this window may mitigate productivity loss and facilitate sustainable return to work.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147481013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use-Results Survey in Japan","authors":"Yoshimasa Ogawa,&nbsp;Kiyotoshi Kuramoto,&nbsp;Atsushi Nakano","doi":"10.1111/luts.70052","DOIUrl":"10.1111/luts.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This report presents the final results of a post-marketing surveillance evaluating the safety of desmopressin orally disintegrating tablets (ODT) in Japanese men with nocturia due to nocturnal polyuria (NP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In total, 1113 Japanese men who received desmopressin ODT for the first time to treat nocturia due to NP were enrolled in a central registry. Of the 1087 patients for which case report forms were collected, 38 did not meet the safety eligibility criteria of the survey. Consequently, the remaining 1049 patients were included in the analysis. The participants were followed for up to 52 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean age of the total population was 75.0 ± 9.6 years. A total of 351 adverse drug reactions (ADRs) were reported in 259 patients, including 11 serious ADRs in 7 patients (0.7%). The most common ADR was hyponatremia, which occurred in 140 patients (13.3%). Among the 19 patients (13.6%) presenting hyponatremia related symptoms, no reports of confusion, seizures, stupor, or coma was recorded. Multivariate analysis identified age ≥ 75 years, a history of benign prostatic hyperplasia, and a lower serum sodium level before treatment as risk factors for the development of hypernatremia after the treatment with desmopressin ODT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The survey provides insights into the safety profile of desmopressin ODT in real-clinical practice in Japan. Patients aged ≥ 75 years, those with underlying medical conditions, and those with abnormal clinical laboratory values, such as reduced renal function or a baseline serum sodium level of &lt; 140 mmol/L, should be closely monitored for the development of hyponatremia during desmopressin treatment for nocturia due to NP.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment-Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet-Rich Plasma in Bladder Pain Syndrome","authors":"Wan-Ru Yu,&nbsp;Tsung-Cheng Hsieh,&nbsp;Ya-Hui Wu,&nbsp;Hann-Chorng Kuo","doi":"10.1111/luts.70057","DOIUrl":"10.1111/luts.70057","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To estimate response to intravesical onabotulinumtoxinA (BoNT-A) injection and platelet-rich plasma (PRP) therapy in females with bladder pain syndrome (BPS) without Hunner lesions, we developed and internally validated treatment-specific predictive models integrating clinical characteristics, bladder functional parameters, and urinary biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Females with BPS who underwent intravesical BoNT-A injection or PRP therapy were retrospectively analyzed. A total of 273 female patients were included in the final analysis. Multivariable logistic regression models were constructed to predict treatment response, defined as a Global Response Assessment score ≥ 2. Model discrimination was assessed using the area under the receiver operating characteristic (ROC) curve. For interpretability, nomogram visualizations and a conceptual framework are provided in the Supporting Information.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The BoNT-A model demonstrated acceptable discrimination (area under the ROC curve: 0.789), whereas the PRP model showed superior discriminatory performance (area under the ROC curve: 0.895). Distinct clinical features and biomarker patterns contributed to each treatment-specific model, suggesting differential underlying mechanisms. Internal validation revealed higher observed response rates when the administered therapy matched the model-predicted higher probability of response, supporting internal model concordance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Treatment-specific models combining clinical, urodynamic, and urinary biomarker data provide mechanistic insight into heterogeneous response profiles to BoNT-A and PRP in females with BPS. While these models may inform future phenotype-guided research and prospective validation, external validation is required before broader clinical implementation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α1-Blocker Treatment: A Multi-Center Prospective Randomized Controlled Study (VATON Study)","authors":"Masaki Yoshida,&nbsp;Yoshinori Nishino,&nbsp;Hiroshi Nagae,&nbsp;Shinobu Kato,&nbsp;Sadaaki Sakamoto,&nbsp;Morifumi Hojo,&nbsp;Toshihide Miyauchi,&nbsp;Shinji Kageyama,&nbsp;Shinichi Takahashi,&nbsp;Hideya Kuroda,&nbsp;Naoki Mori,&nbsp;Yasuhiro Kasagi,&nbsp;Koichi Masunaga,&nbsp;Yoshiyuki Nabeshima,&nbsp;Masanori Nomiya,&nbsp;Koichi Iwashita,&nbsp;Koichi Miyamae,&nbsp;Masayuki Otani,&nbsp;Kazuya Kawahara,&nbsp;Makoto Ikeda,&nbsp;Shinichi Kubono,&nbsp;Nobuhiro Haga","doi":"10.1111/luts.70053","DOIUrl":"10.1111/luts.70053","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the efficacy and safety of vibegron add-on therapy for persistent overactive bladder (OAB) symptoms after <i>α</i>₁-blocker monotherapy for benign prostatic hyperplasia (BPH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eligible patients were aged ≥ 50 years and diagnosed with BPH. All patients had received an <i>α</i>₁-blocker for ≥ 8 weeks, yet had persistent OAB symptoms. Patients were randomized 1:1 to receive add-on vibegron (50 mg) or to continue <i>α</i>₁-blocker monotherapy. The primary efficacy endpoint was the between-group difference from baseline (week 0) to week 12 in total overactive bladder symptom score (OABSS). Secondary endpoints included bladder diary parameters, OABSS subscores; International Prostate Symptom Score total, storage/voiding, quality-of-life score; and patient satisfaction assessed by the Patient Global Impression. Safety was assessed by recording treatment-emergent adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 158 patients were randomized into two groups (<i>n</i> = 79 each). The least-squares mean change in the primary endpoint (OABSS total score) was −1.9 (95% confidence interval [CI]: −2.4 to −1.5) with <i>α</i>₁-blocker monotherapy and −3.3 (95% CI: −3.8 to −2.9) with vibegron add-on therapy; the between-group difference was −1.4 (95% CI: −2.0 to −0.8; <i>p</i> &lt; 0.001), indicating a significant improvement with add-on therapy. Across the secondary endpoints, favorable outcomes were observed. Higher satisfaction was reported in the vibegron add-on therapy group than in the <i>α</i>₁-blocker monotherapy group. Vibegron was well tolerated, and no serious drug-related treatment-emergent adverse events were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Vibegron add-on therapy to an <i>α</i>₁-blocker may be effective and safe for treating BPH with persistent OAB symptoms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12988341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Survey on Real-World Transurethral Surgery Procedures for Bladder Pain Syndrome and Interstitial Cystitis","authors":"Niimi Aya,&nbsp;Akiyama Yoshiyuki,&nbsp;Furuta Akira,&nbsp;Matsuo Tomohiro,&nbsp;Kitta Takeya,&nbsp;Otsuka Atsushi,&nbsp;Mitsui Takahiko,&nbsp;Masumori Naoya,&nbsp;Matsukawa Yoshihisa,&nbsp;Torimoto Kazumasa,&nbsp;Kinjo Manami,&nbsp;Chiba Hiroki,&nbsp;Nomiya Akira,&nbsp;Maeda Daichi,&nbsp;Homma Yukio","doi":"10.1111/luts.70058","DOIUrl":"10.1111/luts.70058","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To investigate real-world practices in transurethral surgeries for bladder pain syndrome (BPS) and interstitial cystitis (IC) in Japan, with a focus on procedural characteristics of hydrodistension (HD) and transurethral elimination of Hunner lesions (TUEH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An internet-based questionnaire was sent to all members of the Society of Interstitial Cystitis of Japan in November 2024. The survey inquired about institutional characteristics, the number of procedures performed in the previous 12 months, and detailed surgical techniques. BPS was defined by the absence of Hunner lesions, and IC by their presence. Responses were analyzed to describe procedural patterns and compare practices between HD and TUEH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 205 eligible members, 86 responded (response rate: 42%). Among them, 52 had performed HD for BPS and 67 had performed TUEH for IC within the study period. Most surgeons distended the bladder to a preset pressure of ≤ 80 cm H₂O for 3–10 min and repeated the procedure at least twice during HD. At TUEH, coagulation was preferred over resection to eliminate Hunner lesions. HD was frequently co-performed, though the sequence of elimination and HD varied. Compared to HD, TUEH more often relied on abdominal palpation rather than fixed pressure, used shorter distension time, and involved longer catheter placement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This nationwide survey highlights contemporary surgical practices for BPS and IC in Japan. These findings may help clinicians evaluate and refine their own approaches to transurethral interventions for these complex conditions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"18 2","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147434211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}